EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
https://doi.org/10.17650/1726-9776-2011-7-4-71-73
Abstract
Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization was noted in 4 (26.7 %) and only 2 (13.3 %) were found to have disease progression. Thus, more than 86 % of patients responded to combination treatment with sustained-release octreotide + dexamethasone. Octreotide treatment caused no serious specific adverse toxic reactions.
About the Authors
D. I. Ganov
Altai State Medical University; Altai Branch, N.N. Blokhin Russian Cancer Research Center, Кussian Academy of Medical Sciences, Barnaul
Russian Federation
Russian Federation
S. A. Varlamov
Altai State Medical University; Altai Branch, N.N. Blokhin Russian Cancer Research Center, Кussian Academy of Medical Sciences, Barnaul
Russian Federation
Russian Federation
References
1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 году. М., 2005.
2. Состояние онкологической помощи населению России в 2009 году. М.: ФГУ МНИОН им. П.А.Герцена Росмедтехнологий, 2009.
3. Клиническая онкоурология. Под ред. Б.П. Матвеева. М., 2011.
4. Isaacs J.T. The biology of hormone-refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263−73.
5. Vainas I.G. Octreotide in the Management of Hormone-Refractory Prostate Cancer. Chemotherapy 2001;47 (Suppl 2);109−26.
6. Mitsiades C.S., Mitsiades N.S., McMullan C.J. et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5(3):221−30.
7. Le Roith D., Bandy C., Yakat S. et al. The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53−74.
8. Reyes-Moreno C., Frenette G., Boulanger J. et al. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 1995; 26:260−9.
9. Koutsilieris M., Mitsiades C.S., Bogdanos J. et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004;1;10(13):4398−405.
Review
For citations:
Ganov D.I., Varlamov S.A. EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER. Cancer Urology. 2011;7(4):71-73. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-4-71-73
Views:
630
Email this article 